Abstract Organs-on-chips (OoCs), also known as microphysiological systems or 'tissue
chips'(the terms are synonymous), have attracted substantial interest in recent years owing …

The high rate of failure during drug development is well-known, however recent advances in
tissue engineering and microfabrication have contributed to the development of …

Tissue engineered scaffolds have emerged as a promising solution for heart valve
replacement because of their potential for regeneration. However, traditional heart valve …

The National Institutes of Health Microphysiological Systems (MPS) program, led by the
National Center for Advancing Translational Sciences, is part of a joint effort on MPS …

The clinical management of malignant tumours is challenging, often leading to severe
adverse effects and death. Drug resistance (DR) antagonises the effectiveness of …

The mitral valve exists in a mechanically demanding environment, with the stress of each
cardiac cycle deforming and shearing the native fibroblasts and endothelial cells. Cells and …

The increasing complexity and cost of drug discovery and medical research requires new
approaches to efficiently develop the next generation of patient therapies. In vitro multiorgan …

Chronic valvular heart disease, with myxomatous degeneration and thickening of the mitral
valve leaflets, is the most common heart disease in dogs. Hypotheses explaining valvular …

Organs-on-chips (OoCs), also known as microphysiological systems or 'tissue chips'(the
terms are synonymous), have attracted substantial interest in recent years owing to their …

Fibrosis of the semilunar cardiac valves clinically manifests as deterioration in late-stage
functional performance. Stenotic insufficiencies, due to either congenital or acquired heart …